Disclosed is an organic amine salt foaming agent, that is, a composite polyurethane foaming agent, comprising: 1) hexafluorobutene; and 2) an alkanolamine salt mixture (MAA), the alkanolamine salt mixture (MAA) contains an organic amine salt compound having the following general formula (I): A.sup.n−[B.sup.m+].sub.p (I); wherein A.sup.n− is one or two or three selected from the following anions: (b) carbonate: CO.sub.3.sup.2−; (c) formate: HCOO.sup.−; (d) bicarbonate: HO—COO.sup.−. A polyurethane foaming method using carbon dioxide and an organic amine in combination is also disclosed, in which carbon dioxide is added to a polyurethane composition for foaming. A method for preparing an alkanolamine carbonate salt with low water content from ammonium carbonate and an epoxide is additionally disclosed, in which a liquid alkanolamine salt mixture is used as a dispersion medium or as a solvent for reaction raw material.

A method for preparing an azo compound includes a first step for producing an X.sub.b molecule by electrolyzing, in a reaction system, a first solution including a hydrazo compound and at least one type of M.sub.aX.sub.b; a second step for oxidizing the hydrazo compound with the generated X.sub.b molecule to obtain a second solution including an azo compound, M.sub.aX.sub.b, and HX; a third step for discharging the second solution outside the reaction system, and separating therefrom a third solution including M.sub.aX.sub.b and HX to obtain a solid azo compound; and a fourth step for introducing the third solution and an additional hydrazo compound equivalent to the hydrazo compound into the reaction system, and electrolyzing a fourth solution including the additional hydrazo compound, M.sub.aX.sub.b, and HX to produce an X.sub.b molecule.

A method for preparing an azo compound includes a first step for producing an X.sub.b molecule by electrolyzing, in a reaction system, a first solution including a hydrazo compound and at least one type of M.sub.aX.sub.b; a second step for oxidizing the hydrazo compound with the generated X.sub.b molecule to obtain a second solution including an azo compound, M.sub.aX.sub.b, and HX; a third step for discharging the second solution outside the reaction system, and separating therefrom a third solution including M.sub.aX.sub.b and HX to obtain a solid azo compound; and a fourth step for introducing the third solution and an additional hydrazo compound equivalent to the hydrazo compound into the reaction system, and electrolyzing a fourth solution including the additional hydrazo compound, M.sub.aX.sub.b, and HX to produce an X.sub.b molecule.

The present invention concerns the manufacture of hydrazinyl compounds useful in the manufacture of pyrazole carboxylic acid and derivatives thereof and processes for the manufacture of agrochemical or pharmaceutical compounds. The invention also concerns hydrazinyl compounds and their use.

The present invention concerns the manufacture of hydrazinyl compounds useful in the manufacture of pyrazole carboxylic acid and derivatives thereof and processes for the manufacture of agrochemical or pharmaceutical compounds. The invention also concerns hydrazinyl compounds and their use.

The present invention concerns the manufacture of hydrazinyl compounds useful in the manufacture of pyrazole carboxylic acid and derivatives thereof and processes for the manufacture of agrochemical or pharmaceutical compounds. The invention also concerns hydrazinyl compounds and their use.

The present invention provides conjugates comprising a sugar such as mannitol and one or more L-DOPA and/or DOPA decarboxylse inhibitors including, inter alia, L-DOPA, carbidopa, benserazide, or a combination thereof, wherein the sugar is conjugated to the carboxyl group of the L-DOPA and/or DOPA decarboxylse inhibitor/ s) via a hydroxyl group of the sugar. The present invention further provides related pharmaceutical compositions and methods of producing the conjugates, as well as methods of use for treating medical disorders responsive to dopamininergic stimulation such as movement disorders including, inter alia, Parkinson's Disease.

The present invention provides conjugates comprising a sugar such as mannitol and one or more L-DOPA and/or DOPA decarboxylse inhibitors including, inter alia, L-DOPA, carbidopa, benserazide, or a combination thereof, wherein the sugar is conjugated to the carboxyl group of the L-DOPA and/or DOPA decarboxylse inhibitor/ s) via a hydroxyl group of the sugar. The present invention further provides related pharmaceutical compositions and methods of producing the conjugates, as well as methods of use for treating medical disorders responsive to dopamininergic stimulation such as movement disorders including, inter alia, Parkinson's Disease.

Provided is a process for preparing the compound 3 (3) or a salt or a solvate thereof, the process comprising the steps of a) Mixing the compound 4 with a mineral acid (4); b) Adding a nitrite salt or an organic nitrite derivative to the reaction mass to form a diazonium salt; c) Adding a sulfur-containing reducing agent to the reaction mass to form a hydrazyl sulfur complex, such as a hydrazyl sulfite complex; d) Hydrolysing the hydrazyl sulfur complex to provide the compound 3 or a salt or solvate thereof; and e) Optionally isolating the compound 3 or a salt or solvate thereof. Further provided is the use of the compound 3 in the synthesis of 3-[5 -Amino-4-(3-Cyanobenzoyl)-Pyrazol-1-yl]-N-Cyclopropyl-4-Methylbenzamide.

##STR00001##

Provided is a process for preparing the compound 3 (3) or a salt or a solvate thereof, the process comprising the steps of a) Mixing the compound 4 with a mineral acid (4); b) Adding a nitrite salt or an organic nitrite derivative to the reaction mass to form a diazonium salt; c) Adding a sulfur-containing reducing agent to the reaction mass to form a hydrazyl sulfur complex, such as a hydrazyl sulfite complex; d) Hydrolysing the hydrazyl sulfur complex to provide the compound 3 or a salt or solvate thereof; and e) Optionally isolating the compound 3 or a salt or solvate thereof. Further provided is the use of the compound 3 in the synthesis of 3-[5 -Amino-4-(3-Cyanobenzoyl)-Pyrazol-1-yl]-N-Cyclopropyl-4-Methylbenzamide.

##STR00001##